Partner Fund Management L.P. bought a new position in shares of Gritstone Oncology Inc (NASDAQ:GRTS) during the third quarter, HoldingsChannel reports. The fund bought 1,065,313 shares of the company’s stock, valued at approximately $14,257,000.

A number of other institutional investors have also recently bought and sold shares of GRTS. Riverhead Capital Management LLC bought a new stake in Gritstone Oncology during the 3rd quarter worth approximately $141,000. Partner Investment Management L.P. bought a new stake in Gritstone Oncology during the 3rd quarter worth approximately $165,000. Alliancebernstein L.P. bought a new stake in Gritstone Oncology during the 3rd quarter worth approximately $285,000. Asymmetry Capital Management L.P. bought a new stake in Gritstone Oncology during the 3rd quarter worth approximately $285,000. Finally, Dean Capital Investments Management LLC bought a new stake in Gritstone Oncology during the 3rd quarter worth approximately $296,000. 43.52% of the stock is currently owned by institutional investors and hedge funds.

Gritstone Oncology stock opened at $30.23 on Thursday. Gritstone Oncology Inc has a 1-year low of $11.22 and a 1-year high of $29.59.

Gritstone Oncology (NASDAQ:GRTS) last released its quarterly earnings results on Wednesday, November 14th. The company reported ($7.60) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.63) by ($6.97). The business had revenue of $0.10 million for the quarter.

In related news, Director Nicholas Simon purchased 333,333 shares of the business’s stock in a transaction on Friday, September 28th. The stock was acquired at an average price of $15.00 per share, with a total value of $4,999,995.00. The purchase was disclosed in a legal filing with the SEC, which is available through this link.

A number of research firms recently weighed in on GRTS. BTIG Research began coverage on shares of Gritstone Oncology in a report on Tuesday, October 23rd. They set a “buy” rating and a $26.00 target price on the stock. Barclays began coverage on shares of Gritstone Oncology in a report on Tuesday, October 23rd. They set an “overweight” rating and a $25.00 target price on the stock. Cowen began coverage on shares of Gritstone Oncology in a report on Tuesday, October 23rd. They set an “outperform” rating on the stock. Finally, Goldman Sachs Group began coverage on shares of Gritstone Oncology in a report on Tuesday, October 23rd. They set a “neutral” rating and a $18.00 target price on the stock.

TRADEMARK VIOLATION WARNING: “Partner Fund Management L.P. Invests $14.26 Million in Gritstone Oncology Inc (GRTS) Stock” was published by Watch List News and is owned by of Watch List News. If you are viewing this piece of content on another publication, it was copied illegally and republished in violation of United States & international trademark and copyright law. The original version of this piece of content can be read at https://www.watchlistnews.com/partner-fund-management-l-p-invests-14-26-million-in-gritstone-oncology-inc-grts-stock/2665553.html.

About Gritstone Oncology

Gritstone Oncology Inc is engaged in the discovery and development of cancer immunotherapies. The company focuses on developing tumor-specific neo-antigens-based therapies for non-small cell lung cancer. Gritstone Oncology Inc has a strategic collaboration with bluebird bio, Inc The company was incorporated in 2015 and is based in San Francisco, California with operations in Cambridge, Massachusetts.

See Also: How Important is Technical Analysis of Stocks

Want to see what other hedge funds are holding GRTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gritstone Oncology Inc (NASDAQ:GRTS).

Institutional Ownership by Quarter for Gritstone Oncology (NASDAQ:GRTS)

Receive News & Ratings for Gritstone Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gritstone Oncology and related companies with MarketBeat.com's FREE daily email newsletter.